Nishida Hiroko

ニシダヒロコ | Nishida Hiroko

Affiliation and department：
Job title： Instructor

Research field (1)： Tumor diagnostics and therapeutics

Research keywords (5)：造血器腫瘍 , 多発性骨髄腫 , 分子標的療法 , モノクローナル抗体 , CD26

Research theme for competitive and other funds (11)：

2020 - 2023 難治性多発性骨髄腫のCD26の発現誘導を制御するHDACアイソフォームの役割
2019 - 2022 Novel anti-cancer therapy against super-enhancer using humanized monoclonal antibody with transportation activity into nucleus
2019 - 2022 核内移行するヒト化抗CD26抗体によるスーパーエンハンサー標的抗がん療法の開発
2019 - 2021 病理検体を用いたCHIPseq法の開発と疾患特異的スーパーエンハンサーの同定
2016 - 2020 難治性多発性骨髄腫のヒト化抗CD26モノクローナル抗体を用いた分子標的療法の開発

Show all

Papers (30)：

Hiroko Nishida, Taketo Yamada. Monoclonal antibody therapies in multiple myeloma: a chalenge to develop novel targets. Journal of Oncology. 2019. ID 6084012
Mutsumi Hayashi, Hiroko Madokoro, Koji Yamada, Hiroko Nishida, Chikao Morimoto, Michiie Sakamoto, Hiroshi Yanagawa, Taketo Yamada. Novel antibody-drug conjugate with anti-CD26 humanized monoclonal antibody and transcription factor IIH (TFIIH) inhibitor, triptolide, inhibits tumor growth via impairing RNA synthesis. Cancers. 2019. 11. 1138. 1-21
Hiroko Nishida, Mutsumi Hayashi, Michiie Sakamoto, Taketo Yamada. CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma. Blood Cancer Journal. 2018. 8. 99. 1-17
Hiroko Nishida, Hiroshi Suzuki, Masao Hori, Katsuyuki Obara. Primary Isolated Bone Marrow Diffuse Large B cell Lymphoma with Long Term Complete Remission. Leukemia Research Reports. 2018. 10. 11-15
Hiroko Nishida. Bone-Targeted Agents in Multiple Myeloma. Hematology Reports. 2018. 10. 12-16

ｍore...

MISC (6)：

Hiroko Nishida. Bone-Targeted Agents in Multiple Myeloma. Hematology Reports. 2018. 10. 12-16
Hiroko Nishida. Bone Targeted Therapy in Multiple Myeloma. International Journal of Hematological Disorders. 2017. 3. 1. 3-6
Hiroko Nishida, Hiroko Madokoro, Hiroshi Suzuki, Mutsumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada. CD26 Is a Novel Target for the Treatment of Tumor Progression and Its Related Osteolytic Bone Disease in Multiple Myeloma. BLOOD. 2015. 126. 23
Hiroko Nishida, Hiroko Madokoro, Hiroshi Suzuki, Michiie Sakamoto, Chikao Morimoto, Taketo Yamada. Humanized Anti-CD26 Monoclonal Antibody Inhibits Osteoclast Bone Resorption Activity Via Blockade Of P38MAPK Signaling In Multiple Myeloma. BLOOD. 2013. 122. 21
Hiroko Nishida, Hiroko Madokoro, Hiroshi Suzuki, Michiie Sakamoto, Chikao Morimoto, Taketo Yamada. Targeting CD26 with Humanized Monoclonal Antibody, As a Novel Approach to Inhibit Human Osteoclast Differentiation and Subsequent Bone Resorption. BLOOD. 2012. 120. 21

ｍore...

Books (6)：

ｍore...

Lectures and oral presentations (60)：

Humanized anti-CD26 monoclonal antibody clonogenic side population cells in multiple myeloma.
(81th Japanese Society of Hematology Annual Meeting 2019)
CD26 is a potential therapeutic target by humanized monoclonal antibody in multiple myeloma.
(第108回日本病理学会総会 2019)
ヒト化抗CD26抗体とTriptolideの抗体薬物複合体はRNA polymeraseを阻害する
(第107回病理学会総会 2018)
CD26 is a potential therapeutic target by humanized monoclonal antibody in multiple myeloma
(23rd Congress of the European Hematology Association 2018)
Humanized anti-CD26 monoclonal antibody has anti-myeloma efficacy for the treatment of multiple myeloma
(59th American Society of Hematology Annual Meeting & Exposition 2017)

ｍore...

Education (1)：

Professional career (1)：

Awards (2)：

2009/09/25 - 文部科学省戦略的基礎研究推進事業文部科学省戦略的研究基盤形成支援事業’疾患モデル動物を用いた病態解明と革新的治療法の開発‘プロジェクト若手研究者研究助成急性リンパ性白血病における癌幹細胞の同定と解析、及び臨床における有用性の評価
2008/05/19 - 慶應義塾医学振興基金 Keio University Resarch Grants for Life Science and Medicine Identification and analysis of cancer stem cells in acute lymphoblastic leukemia and its clinical evaluation.

Association Membership(s) (6)：

日本造血細胞移植学会 , 日本リンパ網内系学会 , 日本臨床腫瘍学会 , American Society of Hematology , 日本内科学会 , 日本血液学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page